WallStreetZenWallStreetZen

NASDAQ: CTXR
Citius Pharmaceuticals Inc Stock

$1.32+0.01 (+0.76%)
Updated Jan 27, 2023
CTXR Price
$1.32
Fair Value Price
$384,090.11
Market Cap
$193.00M
52 Week Low
$0.77
52 Week High
$2.01
P/E
-5.74x
P/B
1.88x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$33.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$28M
Beta
0.4
Next Earnings
Feb 8, 2023
Ex-Dividend
N/A
Next Dividend
N/A

CTXR Overview

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CTXR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CTXR ($1.32) is undervalued by 100% relative to our estimate of its Fair Value price of $384,090.11 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CTXR ($1.32) is significantly undervalued by 100% relative to our estimate of its Fair Value price of $384,090.11 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CTXR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CTXR due diligence checks available for Premium users.

Be the first to know about important CTXR news, forecast changes, insider trades & much more!

CTXR News

Valuation

CTXR fair value

Fair Value of CTXR stock based on Discounted Cash Flow (DCF)
Price
$1.32
Fair Value
$384,090.11
Undervalued by
100.00%
CTXR ($1.32) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CTXR ($1.32) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CTXR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CTXR price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.74x
Industry
12.89x
Market
23.59x

CTXR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
5.18x
CTXR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CTXR's financial health

Profit margin

Revenue
$0.0
Net Income
-$8.0M
Profit Margin
0%
CTXR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$114.0M
Liabilities
$10.6M
Debt to equity
0.1
CTXR's short-term assets ($44.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTXR's short-term assets ($44.56M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTXR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CTXR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.3M
Investing
$0.0
Financing
$0.0
CTXR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CTXR vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CTXR$193.00M+0.76%-5.74x1.88x
PBYI$193.51M-4.07%19.27x8.73x
VRCA$193.55M-1.05%-4.57x4.32x
YMAB$193.89M-2.42%-1.45x1.80x
OLMA$190.55M-0.63%-1.87x0.88x

Citius Pharmaceuticals Stock FAQ

What is Citius Pharmaceuticals's quote symbol?

NASDAQ: CTXR) Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol CTXR. Citius Pharmaceuticals stock quotes can also be displayed as NASDAQ: CTXR.

If you're new to stock investing, here's how to buy Citius Pharmaceuticals stock.

What is the 52 week high and low for Citius Pharmaceuticals (NASDAQ: CTXR)?

(NASDAQ: CTXR) Citius Pharmaceuticals's 52-week high was $2.01, and its 52-week low was $0.77. It is currently -34.33% from its 52-week high and 71.43% from its 52-week low.

How much is Citius Pharmaceuticals stock worth today?

(NASDAQ: CTXR) Citius Pharmaceuticals currently has 146,211,130 outstanding shares. With Citius Pharmaceuticals stock trading at $1.32 per share, the total value of Citius Pharmaceuticals stock (market capitalization) is $193.00M.

Citius Pharmaceuticals stock was originally listed at a price of $6.10 in Jul 6, 2017. If you had invested in Citius Pharmaceuticals stock at $6.10, your return over the last 5 years would have been -78.36%, for an annualized return of -26.37% (not including any dividends or dividend reinvestments).

How much is Citius Pharmaceuticals's stock price per share?

(NASDAQ: CTXR) Citius Pharmaceuticals stock price per share is $1.32 today (as of Jan 27, 2023).

What is Citius Pharmaceuticals's Market Cap?

(NASDAQ: CTXR) Citius Pharmaceuticals's market cap is $193.00M, as of Jan 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Citius Pharmaceuticals's market cap is calculated by multiplying CTXR's current stock price of $1.32 by CTXR's total outstanding shares of 146,211,130.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.